Equity Profile

LLY

Eli Lilly and Company

Health CarePharmaceuticals$1.1T

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Eli Lilly and Company (LLY) is a leading pharmaceutical company focused on developing innovative medicines for various health conditions, including diabetes and cancer. With a market cap of over $1 trillion, Lilly plays a significant role in the healthcare sector, especially as demand for effective treatments continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability, and a strong EPS can indicate effective cost management and revenue growth.

Expected to be around $8.55.

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market share and introduce new products.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LLY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

In Q1 2026, Eli Lilly reported an EPS of $8.55, significantly beating estimates by 21.07%. The stock reacted positively, increasing by 9.80% the following day.

Management Promises & Guidance

Continued focus on innovative drug development.
Commitment to expanding market presence in diabetes and oncology.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, investors are optimistic about Eli Lilly's upcoming earnings, especially given the strong performance in the previous quarter.

Bull Case

If Lilly continues to beat EPS estimates and shows strong revenue growth, it could reinforce its position as a leader in the pharmaceutical industry.

Bear Case

Conversely, any signs of slowing growth or missed expectations could lead to a sharp decline in stock price, as investors may reassess the company's future prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $8.55.

EPS is a critical measure of profitability, and a strong EPS can indicate effective cost management and revenue growth.

Revenue Growth

Not available.

Revenue growth is essential for assessing the company's ability to expand its market share and introduce new products.

Market Reaction

Historically, the stock has moved an average of ±8.60% after earnings.

Understanding how the stock has reacted to past earnings can provide insight into investor sentiment and expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be compared to the expected $8.55?

A strong EPS could reinforce investor confidence, while a miss might lead to a negative reassessment of the company's growth trajectory.

How is revenue growth tracking against previous quarters?

Revenue growth is crucial for sustaining long-term investment interest, and any slowdown could raise concerns.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Eli Lilly to exceed EPS expectations due to strong demand for its diabetes and oncology products.

Supporting Evidence

The company's recent product launches have shown promising sales trends.

Historical performance indicates a strong likelihood of beating EPS estimates.

Options pricing suggests a significant move, indicating heightened investor interest.

Key Risk

If revenue growth falls short of expectations, it could undermine the optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it could set the tone for future growth and investor sentiment.

Bull Confirmed If

An EPS of $8.75 or higher would confirm the bullish outlook.

Bear Confirmed If

An EPS below $8.30 would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±8.56%

Historical Avg

±8.6%

In line with history

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.6% while LLY has averaged ±8.6% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

41.6%

Calls (3.2M)P/C Ratio: 0.97Puts (1.4M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests the stock could rise by around +3.77%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around -8.97%, as seen in previous quarters when expectations were not met.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of new diabetes treatments.
2Any commentary on the competitive landscape in oncology.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on future product launches and pipeline developments.
5Responses to questions about market challenges and regulatory issues.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability, and a strong EPS can indicate effective cost management and revenue growth.

Expected to be around $8.55.

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market share and introduce new products.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

LLY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.79%

Avg Stock Reaction

+0.58%

Last Quarter Recap

In Q1 2026, Eli Lilly reported an EPS of $8.55, significantly beating estimates by 21.07%. The stock reacted positively, increasing by 9.80% the following day.

Management Promises & Guidance

Continued focus on innovative drug development.
Commitment to expanding market presence in diabetes and oncology.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, investors are optimistic about Eli Lilly's upcoming earnings, especially given the strong performance in the previous quarter.

Bull Case

If Lilly continues to beat EPS estimates and shows strong revenue growth, it could reinforce its position as a leader in the pharmaceutical industry.

Bear Case

Conversely, any signs of slowing growth or missed expectations could lead to a sharp decline in stock price, as investors may reassess the company's future prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $8.55.

EPS is a critical measure of profitability, and a strong EPS can indicate effective cost management and revenue growth.

Revenue Growth

Not available.

Revenue growth is essential for assessing the company's ability to expand its market share and introduce new products.

Market Reaction

Historically, the stock has moved an average of ±8.60% after earnings.

Understanding how the stock has reacted to past earnings can provide insight into investor sentiment and expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be compared to the expected $8.55?

A strong EPS could reinforce investor confidence, while a miss might lead to a negative reassessment of the company's growth trajectory.

How is revenue growth tracking against previous quarters?

Revenue growth is crucial for sustaining long-term investment interest, and any slowdown could raise concerns.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Eli Lilly to exceed EPS expectations due to strong demand for its diabetes and oncology products.

Supporting Evidence

The company's recent product launches have shown promising sales trends.

Historical performance indicates a strong likelihood of beating EPS estimates.

Options pricing suggests a significant move, indicating heightened investor interest.

Key Risk

If revenue growth falls short of expectations, it could undermine the optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it could set the tone for future growth and investor sentiment.

Bull Confirmed If

An EPS of $8.75 or higher would confirm the bullish outlook.

Bear Confirmed If

An EPS below $8.30 would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±8.56%

Historical Avg

±8.6%

In line with history

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.6% while LLY has averaged ±8.6% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

41.6%

Calls (3.2M)P/C Ratio: 0.97Puts (1.4M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Eli Lilly beats expectations, history suggests the stock could rise by around +3.77%, confirming the bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around -8.97%, as seen in previous quarters when expectations were not met.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House + Senate

Est. Notional

$4,004.00–$60,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of new diabetes treatments.
2Any commentary on the competitive landscape in oncology.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on future product launches and pipeline developments.
5Responses to questions about market challenges and regulatory issues.